SCOTTSDALE, AZ, July 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – CBD Life Sciences Inc. CBDL is pleased to announce that its wholly owned subsidiary, LBC Bioscience, Inc. (LBC), has finalized the development and is preparing to launch a CBD infused line of coffee products for the US domestic market. The product line will initially consist of four products including a weight loss coffee and a brain booster. It is expected that the products will be available for purchase within the next three to four weeks.
Coffee is one of the most widely consumed beverages worldwide. Millions of consumers all across the United States cannot start their day without a hot cup of coffee. Recent statistics show that American consumers drank on average two cups of coffee per day. In the U.S., the top selling coffee product was dry coffee, which generated $9.37 billion in sales in 2018 while liquid coffee generated about $2.66 billion.
Although people have been drinking coffee for hundreds of years, there are still new trends entering the market every year - the most recent being cold brew and nitro coffee. Cold brew is, as the name implies, brewed with cold temperature water over a longer period and has a higher caffeine concentration than regular coffee. Nitro coffee is infused with nitrogen and can be served like beer. In 2017, cold brew coffee experienced an 80% growth in sales while regular hot coffee sales saw a 3% percent decline. LBC Bioscience, with its introduction of CBD infused coffee, is positioning itself to maximize and leverage the current CBD craze by being one of the first to market with a CBD based coffee line.
About CBD Life Sciences Inc.
CBD Life Sciences Inc. is a publicly traded company having its common shares quoted on the OTC Markets under the symbol ‘CBDL'. The Company's main focus is to identify, evaluate and acquire undervalued opportunities with the objective of increasing shareholder value. The acquisition of LBC Bioscience Inc. is the first in the CBD space and the company is actively searching for additional opportunities within this emerging sector.
About LBC Bioscience Inc.
LBC Bioscience Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. LBC has developed and is retailing/wholesaling a full line of cannabidiol based organic products including: hemp drops, massage oils, pain relief creams, anxiety and sleep supplements, CDB edibles, anti-aging skin solutions and a full line of CBD infused supplements for your pets. LBC's products can be viewed and purchased on the company's website at www.lbcbioscienceinc.com.
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See Optium Cyber Systems, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information: Investor Relations Ten Associates LLC 11529 N. 120th St. Scottsdale, Arizona 85259 USA Telephone: 480-326-8577 Contact: Thomas E. Nelson Email: tenassociates33@gmail.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
